Abstract
Somatic symptom and related disorders (SSRD) are characterized by a mixture of neurological and psychiatric features and include functional neurological (FND) and somatic symptom disorders (SomD). While these complex neuropsychiatric disorders show evidence of genetic susceptibility, there are no genome-wide association studies (GWAS) of SSRD, and the heritability is unknown.
We did a GWAS of a total of 22,203 patients with SSRD, and 1,831,107 controls of European ancestry. We identified one genome-wide significant locus (chromosome 8:65565084) in SSRD, and one additional locus (chromosome 16:49074278) in the SomD subgroup (n cases = 18,536). The observed-scale SNP heritability was estimated to be 7.3 % for SSRD, 15.7 % for FND and 7.7 % for SomD. FND and SomD were strongly genetically correlated (rg=0.94, SE=0.11, p=3.9E-18). SSRD showed significant genetic correlation with psychiatric disorders (highest with anxiety, post-traumatic stress disorders, depression, rg=0.3- 0.8), neurological disorders (migraine, chronic pain, rg=0.4-0.6) and immune-related diseases (rg=0.2-0.3). Functional follow-up analysis of SSRD loci implicated the genes CYP7B1, BHLHE22, and CBLN1, which are involved in metabolic and brain-related processes, suggesting common underlying pathways.
We identified genomic loci associations with SSRD and showed strong genetic correlation between FND and SomD and with neurological and psychiatric disorders, as well as immune-related diseases. The current findings highlight shared underlying pathophysiological processes between SSRD diagnostic categories.
Competing Interest Statement
O.A.A. has received speaker fees from Lundbeck, Janssen, Otsuka, and Sunovion and is a consultant to Cortechs.ai. and Precision Health. The remaining authors have no conflicts of interest to declare.
Funding Statement
Many thanks to our patients, who continue to inspire us to learn more about neurology and psychiatry through their complex conditions. We thank the International Parkinson and Movement Disorder Society (https://www.movementdisorders.org/) for their course on Neuropsychiatry in Movement Disorders, which motivated us to perform this analysis. We thank the participants and researchers contributing to the GWAS investigated in the present study. The authors thank the researchers of the International MS Genetics Consortium (IMSGC) https://imsgc.net/ and consortia for access to summary-level data, as well as all participants who provided DNA samples. We want to acknowledge the participants and investigators of the FinnGen study: https://www.finngen.fi/ [Kurki M. et al., 2023]. The Norwegian Mother, Father and Child Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research. We are grateful to all the participating families in Norway who take part in this ongoing cohort study. We thank the Norwegian Institute of Public Health (NIPH) for generating high-quality genomic data. This research is part of the HARVEST collaboration, supported by the Research Council of Norway (#229624). We also thank the NORMENT Centre for providing genotype data, funded by the Research Council of Norway (#223273), South-East Norway Version 7.0 3 Health Authorities, and Stiftelsen Kristian Gerhard Jebsen. We further thank the Center for Diabetes Research, the University of Bergen for providing genotype data and performing quality control and imputation of the data funded by the ERC AdG project SELECTionPREDISPOSED, Stiftelsen Kristian Gerhard Jebsen, Trond Mohn Foundation, the Research Council of Norway, the Novo Nordisk Foundation, the University of Bergen, and the Western Norway Health Authorities. This research used data from the UK Biobank, a major biomedical database (https://www.ukbiobank.ac.uk/, accession number 27412). We gratefully acknowledge All of Us participants for their contributions, without whom this research would not have been possible. We also thank the National Institutes of Healths All of Us Research Program for making available the participant data examined in this study. The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276. In addition, the All of Us Research Program would not be possible without the partnership of its participants. We gratefully acknowledge support from the Research Council of Norway (#223273, 296030, 324252, 326813, 334920, 344121), European Unions Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie Actions Grant 801133 (Scientia fellowship); the South-Eastern Norway Regional Health Authority (#2020060, IES), KG Jebsen Stiftelsen (SKGJ-MED-021). This project has received funding from the European Unions Horizon 2020 research and innovation programme under grant agreements No 847776 and 964874, EEA grants (EEA-RO-NO-2018-0535, EEA-RO-NO-2018-0573), National Institutes of Health grants U24DA041123 and U24DA055330, NIH 5R01MH124839-02 (PGC4), and the Estonian Research Council (PRG1197). The EstBB part of the research was conducted using the Estonian Center of Genomics/Roadmap II funded by the Estonian Research Council (project number TT17). We would like to thank all participants of the Estonian Biobank who have made this research possible, and the Estonian Biobank Research team Andres Metspalu, Tonu Esko, Reedik Magi, Mait Metspalu, Mari Nelis and Georgi Hudjashov for data collection, genotyping, QC and imputation. Data analysis was carried out in part at the High-Performance Computing Center of the University of Tartu. Individual level data analysis in the Estonian Biobank was carried out under ethical approval 1.1-12/624 (24 March 2020) from the Estonian Committee on Bioethics and Human Research (Estonian Ministry of Social Affairs), using data according to release application 6-7/GI/8746 from the Estonian Biobank from the Estonian Biobank. In the Swedish Schizophrenia Study the computations were enabled by resources provided by the Swedish National Infrastructure for Computing (SNIC) at Uppsala, partially funded by the Swedish Research Council through grant agreement no. 2018-05973. We acknowledge the deCODE genetics/Amgen Inc team, Reykjavik, Iceland and Faculty of Medicine, University of Iceland, Reykjavik, Iceland: Astros Th. Skuladottir, G. Bragi Walters, Thorgeir E. Thorgeirsson, Gyda Bjornsdottir, Hreinn Steffanson and Kari Stefansson for thoughtful comments and providing the data. The acknowledgements for danish groups will be provide later. This work was partly performed on the TSD (Tjeneste for Sensitive Data, projects NS9666S, NS9703S) facilities, owned by the University of Oslo and operated and developed by the TSD service group at the University of Oslo, IT Department (USIT), with resources for computation provided by UNINETT Sigma2, the National Infrastructure for High Performance Computing and Data Storage in Norway.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The regional ethics committee of Norway approved the current study, and local ethics committees approved each of the studies included in the meta-analysis. All participants provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
